AI chatbots can help with scabies education but shouldn't replace doctors.
1 citations
,
June 2023 in “PubMed” New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
October 2018 in “InTech eBooks” Better tools are needed to assess alopecia effectively.
October 2022 in “Hair Transplantation” Digital imaging tools help accurately assess hair transplant candidates.
May 2020 in “Journal of the Dermatology Nurses’ Association” The multimedia tool improved patient understanding of PRP treatment for hair loss.
July 2025 in “Journal of Investigative Dermatology” AI-09 is safe, effective, and reduces wrinkles for up to 6 months.
July 2022 in “Journal of Investigative Dermatology” The conclusion suggests that a new system for measuring hair loss could be created using automated analysis of photographs.
August 2024 in “Journal of the National Medical Association” ChatGPT is more accurate at diagnosing hair disorders in lighter skin tones than darker ones.
2 citations
,
July 2025 in “Drug development & registration” A new algorithm accurately analyzes animal coat and skin colors quickly and easily.
September 2023 in “Journal of the American Academy of Dermatology” Hispanic and Black patients are underrepresented in alopecia areata clinical trials.
Teledermatology effectively diagnoses and manages non-scarring alopecia remotely.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
October 2010 in “Informa Healthcare eBooks”
1 citations
,
January 2016 in “Journal of Microbial & Biochemical Technology” The Free Androgen Index (FAI) is the best indicator of early hair loss in men before age 30.
4 citations
,
March 2024 in “Quality of Life Research” More severe hair loss in alopecia areata greatly impacts patients and caregivers.
May 2025 in “Journal of Investigative Medicine” FAI is a better marker for predicting female hair loss than testosterone or SHBG alone.
2 citations
,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” The conclusion is that a new method could improve the identification of autoimmune targets in alopecia areata, despite some limitations.
2 citations
,
January 2012 Androgenetic alopecia is the only hair loss condition with specific diagnostic criteria in trichoscopy.
January 2026 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deep-learning models can effectively diagnose and assess Alopecia areata using scalp images.
1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Adipose-derived stem cell exosomes and AI can improve personalized skincare by offering anti-aging benefits and precise product customization.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
January 2024 in “Wiadomości Lekarskie” AI in medicine raises many questions and concerns.
August 1995 in “Journal of The European Academy of Dermatology and Venereology” New therapy helps treat hair loss.
December 2024 in “eCommons - AKU (Aga Khan University)” PICAT is a reliable tool for assessing dermatology residents' skills in PRP procedures for hair loss.
2 citations
,
December 2018 in “Novos Estudos Jurídicos” Predictive computational analyses have evolved biopower by using technology to track and predict individual and group behaviors.
2 citations
,
May 2025 in “BMJ Open” Patients with alopecia areata face treatment barriers due to lack of reimbursement and need more support and information.
June 2024 in “British Journal of Dermatology” There are unequal access to wigs for alopecia patients in the UK, needing policy changes for fairness.
2 citations
,
September 2024 in “International Journal of Dermatology” Women and people with skin of color are more likely to be misdiagnosed with alopecia areata.
June 2020 in “Journal of Investigative Dermatology” FDA-cleared devices often fail to produce high-quality platelet-rich plasma consistently.